Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60

Stopped early · Phase 1

Conditions studied: Leukemia

In brief

STUDY BACKGROUND AND PURPOSE: Acute myelogenous leukemia (AML) is a common type of blood cancer in adults, and is more common with increasing age. AML is harder to treat in older patients, with typically poor responses to standard chemotherapy. Patients with AML are typically given intensive induction chemotherapy, but many older patients cannot tolerate the side effects of this therapy. Decitabine has been shown to be active and better tolerated in frail patients with AML; however, most patients still relapse. Recent studies suggest that improving the performance status and fitness of older AML patients prior to induction chemotherapy may help to lessen side effects. This study will test the combination of decitabine treatment with physical exercise in elderly patients with AML who are not candidates for standard induction chemotherapy. STUDY DESCRIPTION: This is a pilot study to test the combination of decitabine treatment with an 8-week physical exercise program in AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy. Patients who are eligible to take part must give their written agreement before they can be enrolled. This study will enroll 20 patients who are not candidates for standard induction chemotherapy. Patients will begin an 8-week program of physical exercise, including 2-3 sessions per week supervised by a physical therapist. During this 8-week period, patients will be given 2 cycles of decitabine therapy (daily infusion for 5 consecutive days of a 28-day cycle). Patients will be followed to assess the safety and tolerability of the program. Patients will also give blood samples that will be used to assess their response to treatment. Patients will be evaluated for their physical fitness before and after the 8-week exercise program and will complete questionnaires to assess their quality of life before and after the program.

Key facts

Study ID

NCT02234037

Run by

Emory University

People needed

3

Starts

2013-11-01

Expected to finish

2016-05-01

Last updated by the study team

2017-01-30

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of AML including de novo, secondary, or with an antecedent hematologic disorder (AHD) according to the World Health Organization (WHO) criteria
• Age ≥ 60 years
• Patient not eligible for (immediate) standard induction chemotherapy based on the opinion of the treating physician and the frailty score
• Provide signed written informed consent
• Be able to comply with study procedures and follow-up examinations
• Adequate heart function with echocardiogram demonstrating ejection fraction ≥ 45% with no evidence of systolic dysfunction
• Adequate renal and hepatic function:
• Total bilirubin ≤ 2x institutional Upper Limit of Normal (ULN); and
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3x ULN; and
• Serum creatinine ≤ 2 times the upper limit of normal
• ECOG performance < 4
• Patients with a history of carcinoma in remission (on no therapy or on hormonal therapy for the adjuvant treatment of breast carcinoma or prostate carcinoma) are included in the study.

You may not qualify if…

• Diagnosis of acute promyelocytic leukemia (APL, French-American-British [FAB] classification M3 or WHO classification of APL with t(15;17)(q22;q12)), (PML/retinoic acid receptor alpha [RARa] and variants)
• Prior treatment with decitabine for myelodysplastic syndrome (MDS) or AML
• Relapsed or refractory AML
• Rapidly doubling white cell count uncontrolled with hydroxyurea
• Coronary artery disease with angina limiting exercise capability
• Joint disease limiting exercise capability
• Investigational agent received within 30 days prior to the first dose of study drug. If received any investigational agent prior to this time point, drug-related toxicities must have recovered to Grade 2 or less prior to first dose of study drug
• Psychiatric disorders that would interfere with consent, study participation, or follow-up
• Systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
• Any other severe concurrent disease, or serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo the proposed therapy
• No social support or inability to attend study-related visits
• Carcinoma requiring systemic chemotherapy or radiation therapy

Where it is running

• Winship Cancer Institute of Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.